secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001628280-23-019604
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharmaceuticals dismisses FORVIS as auditor, appoints CRI for FY2023
-------------------------------------------------------------------------------

- Effective May 18, 2023, dismissed FORVIS as independent auditor; new auditor is Carr, Riggs & Ingram (CRI) subject to engagement letter.
- No disagreements on accounting principles, financial statement disclosure, or audit scope during 2021-2022 and interim 2023.
- FORVIS audit reports for 2021 and 2022 were unqualified, no adverse opinion or modification.
- Company provided FORVIS with disclosures; FORVIS furnished letter to SEC agreeing with statements (Exhibit 16.1).
- No consultations with CRI regarding accounting principles or disagreements prior to appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023019604/0001628280-23-019604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023019604/cpix-20230524.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-019604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer